On Thursday shares of Groupon, Inc. (NASDAQ:GRPN) closed at $7.06. Company’s sales growth for last 5 years was 194.10% and EPS growth for next 5 years is recorded as 27.50%. Groupon Inc. (NASDAQ:GRPN) has left a mark on our digital markets. The popular retail service offered millions of businesses a response to incentivize customers to buy products at a reduced rate in order to spark market demand. The company left its mark as a digital coupon company, but early reports show that Groupon is attempting to explore traditional store venues as well.
Mast Therapeutics, Inc. (NYSEMKT:MSTX) in last trading activity advanced 5.43% to close at $0.49. Company weekly performance is -6.73% while its quarterly performance stands at -13.39%. Mast Therapeutics, Inc. (NYSEMKT:MSTX) is -33.56% away from its 52 week high. On March 24, Mast Therapeutics, Inc. (NYSEMKT:MSTX) reported financial results for the fourth quarter and year ended December 31, 2014. The Company’s net loss for the fourth quarter of 2014 was $7.3 million, or $0.05 per share (basic and diluted), compared to a net loss of $5.7 million, or $0.06 per share (basic and diluted), for the same period in 2013.
On last trading day Cara Therapeutics Inc. (NASDAQ:CARA) decreased -0.69% to close at $10.04. Its volatility for the week is 4.78% while volatility for the month is 5.23%. Cara Therapeutics Inc. (NASDAQ:CARA) monthly performance is -3.28%. On March 26, Cara Therapeutics Inc. (NASDAQ:CARA) reported a fourth-quarter loss of $4.2 million, after reporting a profit in the same period a year earlier. The Shelton, Connecticut-based company said it had a loss of 18 cents per share. The biotechnology company posted revenue of $914,000 in the period. For the year, the company reported that its loss widened to $17.7 million, or 85 cents per share. Revenue was reported as $3.2 million.
Gilead Sciences Inc. (NASDAQ:GILD) in last trading activity moved up 0.73% to close at $98.43. Company weekly performance is -2.62% while its quarterly performance stands at 4.42%. Gilead Sciences Inc. (NASDAQ:GILD) is -15.75% away from its 52 week high. On March 28, it was reported that, John Martin, the CEO of Gilead Sciences Inc. (NASDAQ:GILD), has scored one of his best years ever in 2014, consolidating his position as one of the best-compensated executives of Corporate America. Gilead Sciences has set up a hepatitis C treatment, Sovaldi, which can cost patients around $84,000 for a 12-week treatment. The company announced Martin gained $187.4 million from awarded stock options and restricted shares, but also received compensation valued at $18.9 million last year.
On last trading day AT&T, Inc. (NYSE:T) moved up 0.73% to close at $33.13. Its volatility for the week is 1.01% while volatility for the month is 1.23%. T’s sales growth for past 5 years was 1.60% and its EPS growth for past 5 years was -10.30%. AT&T, Inc. (NYSE:T) monthly performance is -2.56%. AT&T, Inc. (NYSE:T)has more than $2.5 billion in its best-in-class wireless and wired networks in the New York City area between 2012 through 2014, driving a wide range of upgrades to reliability, coverage, speed and performance for residents and business customers. As part of its Project Velocity IP (VIP), an investment plan focused on network enhancement and expansion, AT&T in 2014 made more than 150 wireless network upgrades in the New York City area including new cell sites, addition of wireless and wired network capacity, and new wireless high-speed Internet connections.